These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17431759)

  • 21. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.
    Jones BA; Kasl SV; Howe CL; Lachman M; Dubrow R; Curnen MM; Soler-Vila H; Beeghly A; Duan F; Owens P
    Cancer; 2004 Sep; 101(6):1293-301. PubMed ID: 15368321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.
    Marker KM; Zavala VA; Vidaurre T; Lott PC; Vásquez JN; Casavilca-Zambrano S; Calderón M; Abugattas JE; Gómez HL; Fuentes HA; Picoaga RL; Cotrina JM; Neciosup SP; Castañeda CA; Morante Z; Valencia F; Torres J; Echeverry M; Bohórquez ME; Polanco-Echeverry G; Estrada-Florez AP; Serrano-Gómez SJ; Carmona-Valencia JA; Alvarado-Cabrero I; Sanabria-Salas MC; Velez A; Donado J; Song S; Cherry D; Tamayo LI; Huntsman S; Hu D; Ruiz-Cordero R; Balassanian R; Ziv E; Zabaleta J; Carvajal-Carmona L; Fejerman L;
    Cancer Res; 2020 May; 80(9):1893-1901. PubMed ID: 32245796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
    Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
    J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in breast cancer subtypes with age and race/ethnicity.
    Parise CA; Bauer KR; Caggiano V
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):44-52. PubMed ID: 19800812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
    Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
    Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL
    Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An admixture scan in 1,484 African American women with breast cancer.
    Fejerman L; Haiman CA; Reich D; Tandon A; Deo RC; John EM; Ingles SA; Ambrosone CB; Bovbjerg DH; Jandorf LH; Davis W; Ciupak G; Whittemore AS; Press MF; Ursin G; Bernstein L; Huntsman S; Henderson BE; Ziv E; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3110-7. PubMed ID: 19843668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.
    Ma H; Lu Y; Marchbanks PA; Folger SG; Strom BL; McDonald JA; Simon MS; Weiss LK; Malone KE; Burkman RT; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2013; 15(5):R90. PubMed ID: 24070170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium.
    Bandera EV; Chandran U; Hong CC; Troester MA; Bethea TN; Adams-Campbell LL; Haiman CA; Park SY; Olshan AF; Ambrosone CB; Palmer JR; Rosenberg L
    Breast Cancer Res Treat; 2015 Apr; 150(3):655-66. PubMed ID: 25809092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
    Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
    Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
    Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
    Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.
    Lund MJ; Butler EN; Hair BY; Ward KC; Andrews JH; Oprea-Ilies G; Bayakly AR; O'Regan RM; Vertino PM; Eley JW
    Cancer; 2010 Jun; 116(11):2549-59. PubMed ID: 20336785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.